Hayward, Calif.-based Biolog has garnered another grant from the National Institutes of Health for a new application — this time in the area of antimicrobial drug development — for its Phenotype Microarray cellular array technology.

The additional $450,000 of funding will augment the approximately $2 million in separate grants that Biolog has received in the past three months to support the development of the Phenotype Microarray for applications ranging from detecting bioterrorism agents to functional genomic studies on yeast, Saccharomyces cerevisae.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.